

#### **Review Article**

# Potency and plasma protein binding of drugs *in vitro*—a potentially misleading pair for predicting *in vivo* efficacious concentrations in humans

Dong-Seok Yim<sup>1,2,</sup>\*

<sup>1</sup>Department of Clinical Pharmacology and Therapeutics, The Catholic University of Korea, Seoul St. Mary's Hospital, <sup>2</sup>PIPET (Pharmacometrics Institute for Practical Education and Training), College of Medicine, The Catholic University of Korea, Seoul 06591, Korea

#### **ARTICLE INFO**

Received December 27, 2018 Revised April 28, 2019 Accepted April 30, 2019

\*Correspondence
Dong-Seok Yim
E-mail: yimds@catholic.ac.kr

#### **Key Words**

In vitro
Potency
Unbound concentration

ABSTRACT In drug discovery or preclinical stages of development, potency parameters such as  $IC_{50}$ ,  $K_{ir}$ , or  $K_{d}$  in vitro have been routinely used to predict the parameters of efficacious exposure (AUC,  $C_{\min}$ , etc.) in humans. However, to our knowledge, the fundamental assumption that the potency in vitro is correlated with the efficacious concentration in vivo in humans has not been investigated extensively. Thus, the present review examined this assumption by comparing a wide range of published pharmacokinetic (PK) and potency data. If the drug potency in vitro and its in vivo effectiveness in humans are well correlated, the steady-state average unbound concentrations in humans  $[C_{u\_ss.avg} = f_u \cdot F \cdot Dose/(CL \cdot \tau) = f_u \cdot AUCss/\tau]$  after treatment with approved dosage regimens should be higher than, or at least comparable to, the potency parameters assessed in vitro. We reviewed the ratios of  $C_{u ss,avq}$ /potency in vitro for a total of 54 drug entities (13 major therapeutic classes) using the dosage, PK, and in vitro potency reported in the published literature. For 54 drugs, the C<sub>u ssavo</sub>/in vitro potency ratios were < 1 for 38 (69%) and < 0.1 for 22 (34%) drugs. When the ratios were plotted against  $f_{ij}$  (unbound fraction), "ratio < 1" was predominant for drugs with high protein binding (90% of drugs with  $f_u \le 5\%$ ; i.e., 28 of 31 drugs). Thus, predicting the in vivo efficacious unbound concentrations in humans using only in vitro potency data and  $f_u$  should be avoided, especially for molecules with high protein binding.

### INTRODUCTION

Predicting efficacious concentrations *in vivo* in humans using potency measured *in vitro* (i.e., potency parameters such as  $IC_{50}$ ,  $EC_{50}$ , etc.) and unbound drug concentrations has been used widely at the early discovery or preclinical stages of drug development. The free drug hypothesis, which states that only unbound (free) drug molecules exert effects by binding to targets, has been dogma in pharmacology. If the free drug hypothesis is valid and potency measurements *in vitro* are well correlated with the *in vivo* effects in humans, the steady-state unbound average concen-

trations ( $C_{u\_ss.avg}$ ) achieved in humans by taking the approved dosage regimens should be higher than or at least comparable to the potency parameter values. For example, Smith *et al.* [1] reported that all of the ratios ( $C_{u\_ss.avg}$ /in vitro potency) were > 0.5 (0.5–10) in the exemplified 16 drugs of 10 classes that they cited. In this review, these ratios were further surveyed for major therapeutic classes of drugs using published pharmacokinetic (PK) parameters, dose information in labels, and *in vitro* potency parameters. The ratios in 54 drug entities (13 classes) analyzed were highly variable (0.002–240) compared with the ratios reported by Smith *et al.* [1] (0.5–10). Although our exploration was not exhaustive,



This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial

License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Copyright © Korean J Physiol Pharmacol, pISSN 1226-4512, eISSN 2093-3827

**Author contributions:** D.S.Y. brought up the idea of the review, searched data and wrote manuscript.

232 Yim DS

our results appear sufficient to suggest that the *in vitro* potency and protein binding characteristics of drugs may not always be useful to predict their efficacious dose *in vivo* in humans.

# **DATA ACQUISITION**

# **Potency information**

In vitro potency data were collected from original research articles by searching PubMed and Google Scholar for keywords related to major classes of therapeutic drugs. An example of a keyword combination used for searching is (diabetes or peroxisome proliferator-activated receptor- $\gamma$  [PPAR- $\gamma$ ] as the therapeutic class) + (IC<sub>50</sub>, EC<sub>50</sub>,  $K_d$ ,  $K_i$ , or  $K_m$  for potency). Because our goal was to assess the overall trend, we did not use the exhaustive search methods required for a meta-analysis or systematic review. In the

articles searched, only those that included analysis of at least two drugs in a class and published by a single laboratory were used, so that inter-laboratory or inter-method variation could be avoided. Therapeutic classes excluded from the outset were antibiotics (antibacterial and antifungal) and diuretics. This exclusion criterion was set because the therapeutic dosage regimens of most antibiotics are determined so that the parameters of exposure (area under the concentration-time curve [AUC] and maximum concentration  $[C_{max}]$ ) to the unbound drug are sufficiently higher than the minimal inhibitory concentration (MIC) or minimal bactericidal concentration (MBC), the parameters used to describe antibiotic potency; thus, addressing the in vitro-in vivo correlation in humans is not meaningful for antibiotics. Diuretics, whose effects are better correlated with drug concentrations in the tubular fluid rather than those in plasma were also excluded. Drugs with major active metabolites (parent drug acting as a prodrug only) or having multiple targets were also excluded because interpretation of

Table 1. Drug classes used to estimate the  $C_{u ss,avg}$ /potency ratios

Class	Drugs (unbound fraction %)	Sources (method)								
Ca <sup>2+</sup> channel blocker	Nitrendipine (2), felodipine (0.36), nimodipine (5), nisoldipine (0.3), nifedipine (4.4), amlodipine (0.5), verapamil (9.3), diltiazem (18)	Sun and Triggle [6] $(K_i  for inhibition of calcium induced contraction in physiological salt solution using rat tail artery strips$								
$β_1$ blocker	Carvedilol (2), bisoprolol (66), metoprolol (88), atenolol (94), acebutolol (74)	Baker [7] $(K_d \text{ for } \beta_1 \text{ receptor from human adrenoceptor-expressing CHO-K1 cell:}^3H-CGP 12177 whole cell-binding assay in serum-free media)$								
Statin	Rosuvastatin (12), atorvastatin (2), cerivastatin (1), fluvastatin (0.79), pravastatin (50)	Buckett <i>et al</i> . [8] (inhibition of HMG-CoA reductase in the purified catalytic domain of human liver microsome)								
PPAR-γ agonist	Rosiglitazone (0.2), pioglitazone (1)	Xu et al. [9] EC <sub>50</sub> using recombinant human PPAR-γ receptor								
DPP IV inhibitor	Linagliptin (25), sitagliptin (62), alogliptin (80), saxagliptin (90), vildagliptin (90.7)	Thomas <i>et al</i> . [10] IC <sub>50</sub> using DPP IV extracted from Caco2 cells								
BCR-ABL inhibitor	Dasatinib (4), ponatinib (1), nilotinib (2), bosutinib (4)	Redaelli <i>et al.</i> [11] (IC $_{50}$ from cell proliferation assay on wild-type BCR-ABL transfected murine cells)								
EGFR inhibitor	Imatinib (5), gefitinib (10), erlotinib (7), lapatinib (1)	Kitagawa <i>et al</i> . [12] (IC $_{50}$ from kinase activity assay using ATP as substrate)								
H <sub>2</sub> -blocker	Ranitidine (95), cimetidine (85)	Gustavsson <i>et al.</i> [13] (IC $_{50}$ for histamine-stimulated acid secretion in human gastric mucosal cells)								
PPI	Omeprazole (5), pantoprazole (2), rabeprazole (3.7)	Bastaki <i>et al</i> . [14] IC <sub>50</sub> of acid secretion by rat gastric mucosa								
Protease inhibitor	Indinavir (40), saquinavir (2)	Stevens et al. [15] (pNL4-3 strain of wild-type HIV in MT4 cells)								
Antiepileptics	Phenytoin (11), lamotrigine (45), carbamazepine (24)	Lang et al. [16] (IC <sub>50</sub> of Na <sup>+</sup> channel in mice neuroblastoma cell)								
Antiemetics	Ramosetron (9), granisetron (35), ondansetron (27)	Ito et al. [17] $(K_i \text{ of } 5\text{-HT}_3 \text{ receptor competitive binding in neuroblastoma cell})$								
NSAIDs	Diclofenac (0.5), ibuprofen (0.6), flurbiprofen (1), indomethacin (1), ketoprofen (0.8), naproxen (0.1), celecoxib (3), meloxicam (0.3)	Warner <i>et al.</i> [18] (IC <sub>50</sub> for prostacyclin formation inhibition in human whole blood assay)								

PPAR-γ, peroxisome proliferator-activated receptor-γ; DPP IV, dipeptidyl peptidase IV; EGFR, epidermal growth factor receptor; PPI, proton-pump inhibitor; NSAIDs, nonsteroidal anti-inflammatory drugs.

the ratio is complicated. The potency information for traditional cytotoxic anticancer drugs was not included because published data are rare, and the dosage regimens tend to be closely related to the observed maximum tolerated doses rather than to quantitated efficacies.

From the information obtained in these searches, the potency parameters for 54 drug entities in 13 therapeutic classes are summarized in Table 1, together with their sources and methods. The potency parameters analyzed included receptor binding ( $\beta_1$ -blocker, PPAR- $\gamma$  inhibitor, antiepileptics, etc.), enzyme activity (statins and DPP IV inhibitors), cell proliferation (BCR-ABL inhibitors), or contraction of isolated vascular strips (calciumchannel blockers [CCBs]).

#### **Efficacious concentrations in humans**


We calculated the PK exposures for the 54 drugs whose potency information was collected. The clearance (CL) was obtained from a previous report on i.v. PK parameters [2] and bioavailability (F) from a range of other sources (research articles, drug labels, or www.drugbank.ca). These parameters were used to calculate the unbound average steady-state concentration ( $C_{u\_ss.avg} = f_u \cdot F \cdot Dose/(CL \cdot \tau) = f_u \cdot AUCss/\tau$ ,  $C_{u\_ss.avg}$  at the typical approved dosage regimens indicated on the labels, together with the unbound fraction [ $f_u$ ] and the dosing interval recommended on the label [ $\tau$ ]). Dosing information was obtained from current labels and the median or typically recommended doses were chosen. For a few drugs for

which therapeutic dose AUCs had been reported in patients, we used the reported AUCs rather than the above equation to calculate the  $C_{\rm u\_ss.avg}$ . This information was available for erlotinib and lapatinib (epidermal growth factor receptor [EGFR] inhibitors, reported in research articles [3,4]), dasatinib, ponatinib, nilotinib and bosutinib (BCR-ABL inhibitors, reported in the investigators' brochure or on labels), phenytoin and carbamazepine (antiepileptics, known target concentrations available from therapeutic drug monitoring [5]).

# RATIOS OF UNBOUND CONCENTRATION/ POTENCY

The  $C_{\rm u\_ss.avg}$ /potency ratios were extremely variable (about 100-to 100,000-fold differences even between drugs in the same class) despite there being trends by classes. In contrast to the general expectation (that ratios would be  $\geq$  1), the ratios were < 1 for 38 (69%) and < 0.1 for 22 (34%) of the 54 drugs (Fig. 1A). Even if we used the average total concentration ( $C_{\rm tot\_ss.avg}$ ), the ratios of 17 drugs (26%) were < 1 (data not shown).

In the case of proton-pump inhibitors (PPIs), the low ratios may be explained by their irreversible binding to the proton pump, and the low ratios of statins by the fact that their target is intracellular within hepatocytes. The exposure of the hepatocytes to statins may be sufficiently high because the portal venous blood carries high concentrations of statins, which are higher than the



**Fig. 1. The C**<sub>u\_ss.avg</sub>/**potency** (**IC**<sub>50</sub>,  $K_1$  or  $K_d$ ) ratios. (A) The  $C_{u_ss.avg}$ /potency (IC<sub>50</sub>,  $K_i$  or  $K_d$ ) ratios of 54 drug entities in 13 classes. (B) Ca<sup>2+</sup> channel blockers (CCB): methods 1–5 are those reported by Sun and Triggle [6]. Method 1: IC<sub>50</sub> for rat tail artery contraction (chosen in A). Method 2: IC<sub>50</sub> for rat cardiac papillary muscle contraction. Method 3:  $K_i$  measured using rat heart cell membrane. Method 4:  $K_i$  measured using neonatal rat myocardial cells with K<sup>+</sup> 5.8 mM. Method 5:  $K_i$  measured using neonatal rat myocardial cells with K<sup>+</sup> 50 mM. Smith *et al.*: Data cited in the article by Smith *et al.* [1]. PPAR-γ, peroxisome proliferator-activated receptor-γ; DPP IV, dipeptidyl peptidase IV; EGFR, epidermal growth factor receptor; NSAIDs, nonsteroidal anti-inflammatory drugs; nife, nifedipine; amol, amlodipine; nitren, nitrendipine; felo, felodipine; nimo, nimodipine; nisol, nisoldipine; verap, verapamil; dilti, diltiazem.


234 Yim DS

peripheral venous concentrations, to the liver immediately after passing the intestine (first-pass effect). Thus, at the effect site (inside the hepatocyte), statin concentrations may be much higher than those in the peripheral venous blood, which in the present analysis were found to be much lower than the potency parameters. This explanation may also be applicable to other drugs that target intracellular receptors of hepatocytes.

When the ratios were plotted against  $f_{\rm u}$  (Fig. 2), the "ratio < 1" phenomenon was distinct for drugs with high protein binding (27 of 30 [90%] drugs with  $f_{\rm u}$  5% vs. 10 of 24 [42%] drugs with  $f_{\rm u}$  > 5%). The average ratios (unbound) of statins and CCBs were < 0.1. The finding that a ratio < 1 was most common for drugs with  $f_{\rm u}$  ≤ 5% (Fig. 2) implies that the accuracy of the protein-binding assay needs to be improved, especially at the upper extremes. Because 3 of the 5 statins and all of the 3 PPIs listed in this review had  $f_{\rm u}$  ≤ 5% (Table 1) [6-18], their low ratios mentioned above may be also related to the low  $f_{\rm u}$  (Fig. 2).

# IN VITRO POTENCY VARIES DEPENDING ON THE ASSAY METHOD

Because the potency measured *in vitro* varies according to assay methods and laboratories, the ratio for each drug reported herein may not be dependable. However, the trend observed across the 13 classes indicates that the traditional, free drug hypothesis-based approaches may be misleading when the data are obtained from *in vitro* studies alone without corroborating data from *in vivo* studies in animals or humans. An example of a study that took a similar approach to ours is the report of Smith *et al.* [1] concerning the effect of plasma protein binding on drug efficacy *in vivo* in humans [1]. In that study, unlike in ours, the ratios ( $C_{\rm u}$  <sub>ss.ave</sub>/potency) of all 16 drugs analyzed were > 0.5. Be-



**Fig. 2.** C<sub>u. ss.avg</sub>/**IC**<sub>50</sub> **ratios plotted against the unbound fraction.** The ratios tended to be lower, especially when the unbound fractions were < 5%. This implies that currently used methods for protein-binding assay may overestimate the protein-bound fraction in highly protein-bound drugs. Low ratios that may be explained by irreversible target binding (PPI) or intrahepatic target (statin) were marked with filled symbols. PPI, proton-pump inhibitor.

cause the 16 drugs used in that study, with the exception of nifedipine and amlodipine, do not overlap with the drugs in our list, the two reports cannot be compared directly. However, one possible explanation of the differences is that the measured potency values tend to be highly variable because of the different methods used. For example, the ratios of nifedipine and amlodipine cited by Smith et al. [1] were 1.5 and 0.5, respectively. However, as indicated in Fig. 1B in our report, they were 0.44 (nifedipine) and 0.001 (amlodipine) when the IC<sub>50</sub>s for rat tail artery contraction were measured [6]. Indeed, in the same report, the ratios calculated using potency values obtained from other methods such as  $IC_{50}$  for rat papillary muscle contraction or  $K_i$  for rat heart muscle binding (radioligand) [6] were highly variable: 0.07-0.45 for nifedipine and 0.00005-0.05 for amlodipine. Of the several methods for measuring potency described in that article, the method of tail artery contraction (leftmost column in Fig. 1A) was chosen because it was considered to emulate most closely the situation in vivo in humans. Even when the same type of method (ligand binding assay) was used, the resulting potency values  $(K_i)$  varied by 100-fold depending on the concentrations of potassium used in their experiment (5.8 mM vs. 50 mM) as illustrated in Fig. 1B (method 4 and method 5).

# WHAT CAUSES SUCH DISCREPANCIES BETWEEN IN VITRO POTENCY AND IN VIVO EFFICACIOUS CONCENTRATIONS IN HUMANS?

The causes of in vitro-in vivo discrepancies in humans can be discussed from a few viewpoints. There are many cascading steps between target occupation in vitro and measurable responses in vivo in humans. Thus, the signal initiated by the occupation of a target molecule may be amplified or reduced while passing through these cascade steps; e.g., if the signals are amplified, the effect in vivo in humans may be high despite low target occupancy (and thus low potency in vitro) unless the potency marker exists downstream of the cascade. When the target binding site is intracellular, the target occupancy will be more closely correlated with the intracellular unbound concentration. In theory, the unbound concentrations in intracellular space are influenced by the plasma unbound concentration, the proportion of the drug ionized ( $pK_a$ ), lipid solubility, and the presence and activity of membrane transporters. However, unless there is evidence for huge discrepancies between the intracellular and extracellular unbound drug concentrations, the existence of an intracellular target (e.g., for statins, EGFR inhibitors, and PPIs on our list) alone is not sufficient to justify the in vitro-in vivo discrepancies in humans reported here.

*In vitro-in vivo* discrepancies in humans may also arise from the inherent limitations of all *in vitro* biological studies. *In vitro* studies may provide clues about efficacy, but their implications

should not be overemphasized. When a test is performed *in vitro* using a test molecule and another known competitor drug that acts on the same target, the results may give some indication as to the relative potency of the test molecule that can be used for decision-making. However, if the test molecule acts on a novel target for which no known drug exists, *in vitro* results alone for the test molecule should not be used when making critical decisions about prediction of efficacious concentrations in humans.

### CONCLUSION

Because, as shown in Fig. 1, discrepancies between the potency in vitro and effects in vivo in humans are so widespread, caution is needed in the interpretation of data obtained in vitro; all the in vitro methods currently used for assaying potency should be regarded as ancillary screening tools that cannot be used to infer the in vivo effects in humans dependably. Predicting efficacious unbound concentrations in vivo in humans using potency data obtained in vitro is not a reasonable approach, particularly for molecules with high protein binding ( $f_{v}$  < 5%). The fate of candidates should not be determined by the  $f_{ij}$  and potency data from in vitro studies alone, before comparing their effects in animal models in vivo. These observed discrepancies may not be new to experienced researchers working in the areas of drug discovery or early preclinical development. However, to our knowledge, the existence of in vitro-in vivo discrepancies in humans or their implications have never been properly addressed. Therefore, this review is the first to raise the issue of this discrepancy and its relationship to plasma protein binding and the caveats associated with it.

#### **ACKNOWLEDGEMENTS**

The author thanks Drs. Soohyun Bae and Wansu Park for their excellence in searching and assessing PK/PD parameters of the drugs cited in this article and Prof. Seounghoon Han for his valuable comments.

# **CONFLICTS OF INTEREST**

The author declares no conflicts of interest.

# **SUPPLEMENTARY MATERIALS**

Supplementary data including one figure can be found with this article online at http://pdf.medrang.co.kr/paper/pdf/Kjpp/Kjpp2019-23-04-01-s001.pdf.

#### REFERENCES

- Smith DA, Di L, Kerns EH. The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery. *Nat Rev Drug Discov.* 2010;9:929-939.
- 2. Obach RS, Lombardo F, Waters NJ. Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. *Drug Metab Dispos*. 2008;36:1385-1405.
- Chiorean EG, Porter JM, Foster AE, Al Omari AS, Yoder CA, Fife KL, Strother RM, Murry DJ, Yu M, Jones DR, Sweeney CJ. A phase I and pharmacokinetic trial of erlotinib in combination with weekly docetaxel in patients with taxane-naïve malignancies. *Clin Cancer Res.* 2008;14:1131-1137.
- Liao J, Gallas M, Pegram M, Slingerland J. Lapatinib: new opportunities for management of breast cancer. Breast Cancer. 2010;2:79-91.
- Eadie MJ. Therapeutic drug monitoring--antiepileptic drugs. Br J Clin Pharmacol. 1998;46:185-193.
- 6. Sun J, Triggle DJ. Calcium channel antagonists: cardiovascular selectivity of action. *J Pharmacol Exp Ther.* 1995;274:419-426.
- 7. Baker JG. The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors. *Br J Pharmacol.* 2005; 144:317-322.
- Buckett L, Ballard P, Davidson R, Dunkley C, Martin L, Stafford J, McTaggart F. Selectivity of ZD4522 for inhibition of cholesterol synthesis in hepatic versus non-hepatic cells. *Atherosclerosis*. 2000; 151:41.
- Xu HE, Lambert MH, Montana VG, Plunket KD, Moore LB, Collins JL, Oplinger JA, Kliewer SA, Gampe RT Jr, McKee DD, Moore JT, Willson TM. Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors. *Proc Natl Acad Sci U S A*. 2001;98:13919-13924.
- 10. Thomas L, Eckhardt M, Langkopf E, Tadayyon M, Himmelsbach F, Mark M. (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylm ethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors. *J Pharmacol Exp Ther.* 2008;325:175-182.
- 11. Redaelli S, Mologni L, Rostagno R, Piazza R, Magistroni V, Ceccon M, Viltadi M, Flynn D, Gambacorti-Passerini C. Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors. *Am J Hematol.* 2012;87:E125-E128.
- 12. Kitagawa D, Yokota K, Gouda M, Narumi Y, Ohmoto H, Nishiwaki E, Akita K, Kirii Y. Activity-based kinase profiling of approved tyrosine kinase inhibitors. *Genes Cells*. 2013;18:110-122.
- Gustavsson S, Mårdh S, Norberg L, Nyrén O, Wollert S. Omeprazole, cimetidine, and ranitidine: inhibition of acid production in isolated human parietal cells. *Scand J Gastroenterol.* 1985;20:917-921.
- 14. Bastaki SM, Chandranath I, Garner A. Comparison of five antisecretory agents acting via gastric H<sup>+</sup>/K<sup>+</sup>-ATPase. *J Physiol Paris*. 2000;94:19-23.
- 15. Stevens R, Kakuda T, Bertz R, Mo H, Molla A, Rode R, Kempf D. Inhibitory quotient of protease inhibitors using a standardized determination of IC50. Paper presented at: 4th International Workshop on Clinical Pharmacology of HIV Therapy; 2003 Mar 27-29;

236 Yim DS

- Cannes, France.
- Lang DG, Wang CM, Cooper BR. Lamotrigine, phenytoin and carbamazepine interactions on the sodium current present in N4TG1 mouse neuroblastoma cells. *J Pharmacol Exp Ther*. 1993;266:829-835.
- 17. Ito H, Hidaka K, Miyata K, Kamato T, Nishida A, Honda K. Characterization of YM060, a potent and selective 5-hydroxytryptamine3
- receptor antagonist, in rabbit nodose ganglion and N1E-115 neuro-blastoma cells. *J Pharmacol Exp Ther.* 1992;263:1127-1132.
- 18. Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full *in vitro* analysis. *Proc Natl Acad Sci U S A*. 1999;96:7563-7568.

F; Br.J.clin.Pharmac.(1 transmembrane or extracellular domain E: detechank ca. Doce transmembrane or extracellular domain	F; CPT. 2002;72(5):56(transmembrane or extracellular domain	F; drug bank.ca, Dose transmembrane or extracellular domain	9.88828 JPET 274:4 rat tail artery contrac F; Br J Clin Pharmaco transmembrane or extracellular domain	transmembrane or extracellular domain	extracellular domain	extracellular domain	extracellular domain	extracellular domain	extracellular domain	extracellular domain	extracellular domain	intracellular	aintracellular	ıntracellular	(Intracellular	intracellular	indecellular.	intracellular	5 extracellular domain	P extracellular domain	5 extracellular domain	5 extracellular domain	5 extracellular domain	intracellular	intracellular	intracellular	intracellular	intracellular	Fintracellular	intracellular	is extracellular	intracellular irreversible	intracellular, irreversible	intracellular, irreversible	y intracellular	3- intracellular	e transmembrane?	transmembrane?	e transmembrane?	extracellular	extracellular	) drugs	) drugs		) drugs	) drugs	xos 1993; 14: 491-502	2000, 38(3):225-242
			ry contrac F; Br J Clin Pharmac	52	20 14	9	표다른 타 CL/F	oetal selective	II, Kd value	ll, Kd value	1.359692 Br JPharm:CHO-K1 ceactive metabolite 존재	1.387336 Am J Card doned human liver microsome	0.509286 Am J Card cloned human liver nCL, fu, F; Clin Pharmaintracellular	0.178657 Am J Card cloned human liver microsome	0.15625 Am J Card doned human liver n.C.ss,ave. C.ss, tu; Br J Cintracellular	0.27.299 Am J Card doned human liver microsome	ACCUSA MILLA CALLA CONTROL HUMBAN INVENTINCIOSOTTIE	active met CL/E	1657443 IPET 325-1 DPP-4 extracted from CL/F Clin PK 2012: 5 extracellular domain	17.16456 JPET 325:1 DPP-4 extracted fron CL/F. Clin *추가 연구extracellular domain	7.612183 JPET 325:1 DPP-4 extracted fron CL/F. Clin PK 2012; 5 extracellular domain	0.155586 JPET 325:1 DPP-4 extractive met CL/F. Clin PK 2012; 5 extracellular domain	4.269351 JPET 325:1 DPP-4 extracted from CL/F. Clin PK 2012; 5 extracellular domain	active metCss,ave	ype BCK-/ CSS, ave	ype BCR-7Css,ave	ype BCR-ABL		3400.245 Genes to (kinase asstactive metCss,ave. Clin Cancer Fintracellular	y Css,ave	2.465139 Scand J Gastroenterolow conc FF, tau, Dose; Goodmeextracellular	2.525907 Scand J Gastroefferolow conc fr, tau, Dose, Goodine extracellular 1732368 Physiol Paris 22000 94(1):19-23	(1):19-23.	(1):19-23.	11.6414 4th International Workshop on Clinical Pharmacology intracellular	2.676625 4th International Wor(WS) Saquinavir - ritonavir와 병·intracellular	1.025182 JPET 1993; mice neuroblastoma TDM target conc use transmembrane?	0.924797 JPET 1993; mice neuroblastoma cell, current	0.241855 JPET 1993; mice neuroblastoma TDM target conc use transmembrane?	oma cell K.	ama cell Ki	17.00133 PNAS 199! Whole blood assay ICClin Pharn DMD 670 drugs	Whole blood assay IC50 DMD 670 drugs	Whole blood assay ICFDA label,	Whole blood assay ICClin PharmDMD 670 drugs	Whole blood assay IC50 DMD 670 drugs	blood assay ICBiopharm Drug Dispos 1993; 14: 491-502	Whole blood assay ICClin Pharmacokinet, 2000, 38(3):225-242 Whole blood accavitingamm rec50.55-59 (2001)
10.55306 JPET 274:419-426, 1995 0.700704 IPET 274:419-426, 1995	89.52522 JPET 274:419-426, 1995	0.737125 JPET 274:419-426, 1995	T 274:4 rat tail arte	0.309621 JPET 274:419-426, 1995	0.931508 JPET 274:419-426, 1995	0.639022 JPET 274:419-426, 1995	9.999675 Br JPharmiCHO-K1 ce Line FricLi/F	2.226697 Br JPharmiCHO-K1 cebeta1 selective	2:59478 Br JPharm: CHO-K1 cell, Kd value	1.700848 Br JPharm CHO-K1 cell, Kd value	JPharm; CHO-K1 cea	1) Card doned hun	J Card cloned hum	) Card cloned hun	) Card doned hun	) Card doned hun	0.23730 AIII.) Cald dolled fluit		T 325-1 DPP-4 extra	T 325:1 DPP-4 extra	T 325:1 DPP-4 extra	T 325:1 DPP-4 extra	T 325:1 DPP-4 extra	13.05056 Am J Hem CELL wild active met Css, ave	49.08232 Am J Hem CELL Wild type BCR-F-CSS,ave	112.9198 Am J. Hem.CELL Wild type BCR-7-CSS, ave 6.835382 Am J. Hem.CEL J. Wild type BCR-4-Css ave	4.777937 Am J Hem CELL wild type BCR-ABL	768.1239 Genes to (kinase assay	nes to (kinase asse	529.7632 Genes to (kinase assay	nd J Gastroenterol	2.52.5907 Scand J Gasupenterolow conc. 1.732.368 Physiol Paris 22000 94(1):19-23	7.245684 Physiol Paris, 22000 94(1):19-23.	0.498334 Physiol Paris.?2000 94(1):19-23.	International Work	International Wor(	T 1993; mice neuro	T 1993; mice neuro	T 1993; mice neuro	46.2   152 J Pharmac neuroblastoma cell K. 2 073018   I Pharmac neuroblastoma cell Ki	7 960994 J Pharmac neuroblastoma cell Ki	AS 1995 Whole bloc	Whole bloc	Whole bloc	Whole bloc	Whole bloc	Whole bloc	Whole bloc
1 10.55306 JPE						504.17 0.639022 JPE					194.94 1.359692 Br.			_		5.11 0.27.299 Am		15.56 2.087447 PN		19 17.16456 JPE	24 7.612183 JPE	50 0.155586 JPE	62 4.269351 JPE		1.17 46.68232 Am			1 768.1239 Ger	,	9.61 529.7632 Ger	1 2.465139 Sca	5 2.523907 Sca 1 1732368 Phy	1.67 7.245684 Phy			5.88 2.676625 4th			2.41 0.241855 JPE	22.2 2.073.018 LPI			3.258179	3.844836	1.599679	0.840829	6.994266	0.8372
1 00	69.81	0.05				2/4./6 5(					981.84 15	-	0.09	0.02		0.07	0.0	- 11		487.93	352.69	16.9	579.35	- 3	# 15 15			-	4.56	99.0	- 5	4.50	2.79	0.51	-	200	-	5.73	1.24	- 17.								
0.00342		0.00017		0.00113	0 0	7 0		0.39752	m			0.00014	0			E-25	22.5-19					0.00054		0.00172	1,6306		-	76.4771	182.3261		0.04264	0.06144 64 F-22	E-08	E-12	0.0013	0.01117		0	2.88		2 88							
0.48 0.21106 0.0 1.24 0.00256 0.0	4.47626	0.00221	0.43508	0.00155			0.19999	1.46962			1.00617 1.	0.16648		6/10000 01		27.6 0.00216 1.77.E-25	0.12009 3.	0.020.0	0.41436		24 6.08975 4.3	50 0.14003 0.0	62 3.8723 0.0	_	2.1 U.46682 U			0.51 76.81239 76	238.0172	5.29763	200 2.34188 0.0	0.08662 5			4.65656	0.05353				2.02 0.72556			7200 0.01955	5500 0.03845	1000 0.016			870 0.02512
												539	558.64	459.55						523.32	339.39	315.41	303.4	900	292	158		446.9					383.37	443	_				-	219.55 U.S			206.29 7;					
0.00164 360.361		0.0004 388.414		0.04889 408.879	454.602	414.519		5.88326 325.443	267.364		m	0.00075 481.539	55	45		-24 411.466						0.0269 31			0.8646 532.5595			39.0033 44	136.7446 393.4357		8.5281 314.404	-20 345.416		(4)		7.5937 670.841	252.268	256.091	236.269	77 2	5 ~	296.	Ŕ	244	357.787	254.281	230.	381.372
0.10131 0.00164					7.44153	27.83578			125.5873				0.08352	0.01/8/	0.0875	0.05952 4.90.E-24	3.01.24 & 30.E			4	146.1539 101.2594	7.0014 0.0			20.0736 0.8	4	1~	39.1743 39.0			-	2 5986 1 69 F-20	7.2457 1.09.E-06	1.3276 1.48.E-10			6540.663	37870.43	8126.331	1.465.6	15.1108	3.23	140.753	211.466	15.997	19.507	195.839	21.851
0.59953 0.1		0.02046 0.0		0.08845 0.0				54.16909 21.7				8.37726 0.8	0.0	0.0		326525 0.0						53.1743 7.	Ñ		1.5914 U.			39.3458 39.	205.7653 178.			130.967 2				102.2391 36.			0 812	5 -	0 15		14	21	-	#DIV/0i 19	19.	Α,
				9	#DIV/0i	#DIV/OI			0	0			#DIV/0i	#DIV/0i		0 32					126.5742 202	0.0298 53	0.0013 357		86.4561			390.0332 39	1953.494 205		8.9769 270					m	#DIV/0i	#DIV/0i	#VALUE!	#DIV/0I	#DIV/OI					#DIV/0i #DI		
5.06547 0.08198	-								142.7129						1.75	7.53452						7.7793			98.0329 8			391.7432 39			493.0278									4.3872 #L			3458.89	21146.6	629.65		195839.4	728.364
		6.82157 1		17.68966 13	0 0	ST 0		82.07437 32	14			69.81047 7	0 4	0 0		0 413,3222 7			5	m	253.3583 18				9 9251.651			393.4582 39	2939.505 25			261934					0 29		0 33		0		23	2	15	0 #DIV/0! 24	19	7 7
0.000003 29.97655				**	#DIV/0!	#DIV/0i		0.0029 8.				_	#DIV/0i	#DIV/0!		0 0			0.0003		0.043 25				0.046			0.1743 39	0.7686 23		0.0028 28						#DIV/0i	#DIV/0i	#VALUE!	#DIV/0I	i0/AlG					# 0		
0.00183	. 6	9900000	0.00856	9	œ ·	_	0.00724	0.01073	0.03816	-	m	-	m	0.000082 #		0.0031	0.00402	0.09000	0.0008	0.1707	0.062	0.0025	0.0803	0.0115	1.0522	0.1508	1.4848	0.1751	1.0033	1.5083	0.155	0.0309	0.1389	0.0129	0.8267	1.221	ı 01	21.5517 #	00 1	0.001225	. 4	-	4.839	5.165	0.572	0.62	45.094	0.278
0.0108		0.00265	0.11392	0.00723				0.02671			1.34482	0.03362				0.17007	0.112.0	0.42620	0.0016	0.4756	980'0	0.0186	1.1972	9600:0	13103	0.1564	2.2646	0.1758	1.1565		0.8957	0.9048	2.5882	0.3377	8.711	3.4293			•									
8 ;	8	82	10	50	240	0L7	3.125	2	100	S	400	8	15	0.4	9	8 9	₽ '	9 8	3 11	100	22	3.75	100	100	4 6	8 6	400	250	150	1250	ST 6	ş 8	9	10	800	20000		55		0.3	1 00	23	200	25	25	100	250	200
* *	4	24	24	54	24.5	54	12	*	24	24	24	54	75	24	54	7 7	\$ 7	57 75	7 7	24	24	24	24	75 75	4 5	7 7	24	24	24	24	12	7 7	54	24	80	12		12	ě	\$ 78	1 2	. «o	12	80	80	24	12	* *
0.23	0.035	0.05	0.63	0.77	0.275	0.4	- ;	0.8	0.5	0.5	0.4	0.2	0.14	0.6	0.05	0.25	2 6	6.3	0.295	0.87	-	0.75	0.85	0.24			0.98	9.0	9.0		0.5	0.76	0.77	0.52	0.625	0.04		-	•	- 4	90	6.0	-	-	-	-	-	0.80
0.246		0.164	0.554	0.025			000	0.093			0.353	0.388				2.286	1.020	0.135	0.071	0.107	0.029	0.316	0.621	0.231	20.02	0.046	0.038	0	0.017		0.48	2.1	0.776	1.091	1.317	0.217												
0.02	0.05	0.003	0.044	0.005	0.093	0.18	0.02	99.0	0.88	0.94	0.74	0.12	0.02	10.0	0.05	0.0079	0.00	0.002	0.25	0.62	0.8	0.9	0.907	0.04	10.0	0.02	0.05	0.1	0.07	0.01	0.95	0.05	0.02	0.037	0.4	0.02	0.11	0.45	0.24	0.09	0.27	0.005	900'0	0.01	0.01	0.008	0.001	0.03
105	8.87	63	30.66	29.4	75.6	54.6	35.994	15.54	54.6	10.5	45	46.2	37.506	12.18		67.2	00.0	6.73	78.47	21.24	16.8	47.76	44.1	578	31.8	189	=	35.7	3.95		40.32	35.28	9.24	16.8	75.6	54.6		0.58		38.22			m	1.21	5.46	6.72	0.462	30
25	:	15	7.3	7	18	13	8.57	3.7	13	2.5	10	=	8.93	5.9		16	(	0.05		5.1		11.4	10.5								9.6		2.2		18					0	- 00	3.5	0.82			1.6		0.13
6.1		5.5		17				2.4	_		1.7	1.7	_	_	_	0.42					8.3	2.2		35.7857	10.0007	86857	4.13	1400	3.31428		12	0.24			0.82	3.6		e	pine	_		0.22	0.15		_	0.13	0.2	455 (L) 0.15
Nitrendipii Felodipine		_				diltiazem	Beta block carbedilol	Beta block bisoprolol	2 Beta block metoprolo	Beta block atenolol	2 Beta block acebutolol					n Fluvastatin		4 PPAR-1 ag ROSigiliazo 4 PPAR-1 ag Pioglitazor	5 DPP IV inh I inaclintin	5 DPP IV inhSitagliptin	5 DPP IV inhAlogliptin	5 DPP IV inhSaxagliptir	5 DPP IV inhVildagliptii	6 BCR-ABL i dasatinib	6 BCR-ABL i ponatinio	6 BCR-ABL I fillotifild 6 BCR-ABL i hosutinib	6 BCR-ABL i Imatinib	7 EGFR inhit gefitinib	7 EGFR inhit erlotinib	7 EGFR inhit lapatinib	8 H2-blocke ranitidine	9 PPI omeniazol			10 Protease ir Indinavir	10 Protease ir Saquinavir	11 AntiepilepiPhenytoin	11 AntiepilepiLamotrigine	11 AntiepilepiCarbamazepine	12 antiemetic ramosetron 12 antiemetic granistron	12 antiemetic ondansetror	VIDs diclofenac		NDs flurbiprofe	MDs indometha	VIDs ketoprofer	VIDs naproxen	13 NSAIDs (C celecoxib 455 (L)
1 008	1 CCB	1 CCB	1 CCB	1 CCB	1 GB	1 50	2 Bets	2 Beta	2 Beta	2 Beta	2 Beta	3 statin	3 statin	3 statin	3 statin	3 statin	o stdull	4 PPA	2 000	5 DPP	5 DPP	5 DPP	5 DPP	6 BCR	9 BCK	6 BCR	6 BCR	7 EGF	7 EGF.	7 EGF.	8 H2-1	1-ZE 0	ldd 6	9 PPI	10 Prot	10 Prot	11 Anti	11 Anti	11 Anti	12 antic	12 antik	13 NSAIDs	13 NSAIDs	13 NSAIDs	13 NSAIDs	13 NSAIDs	13 NSAIDs	13 NSA

Supplementary Fig. 1. Because excel format is not allowed by JKPP as a supplement format, a screenshot was attached. If you wish to see the raw data in excel format, please contact the corresponding author (yimds@catholic.ac.kr).